medigraphic.com
SPANISH

Dermatología Cosmética, Médica y Quirúrgica

Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2007, Number 2

<< Back

Dermatología Cosmética, Médica y Quirúrgica 2007; 5 (2)

Melasma: Consensus of the Mexican Working Group for the Study of Pigmentary Disorders

Arellano-Mendoza I, Arias-Gómez I, Barba-Gómez JF, Elizondo-Rodríguez A, García-Vargas A, Garza-Buentello E, Juárez-Navarrete L, León-Dorantes G, López-Ibarra M, Mercadillo-Pérez P, Muñoz-Hink H, Ocampo-Candiani J, Ortiz-Becerra Y, Podoswa-Ozerkovsky N, Ríos-Ávila ME, Rodríguez-Castellanos MA
Full text How to cite this article

Language: Spanish
References: 14
Page: 112-122
PDF size: 1393.50 Kb.


Key words:

Melasma, Treatment guide, Mexican Group for the study of Pigmentary Disorders (Grupo Mexicano para el estudio de los Trastornos Pigmentarios).

ABSTRACT

Melasma is an acquired hyperpigmentation of the face that represents one of the main causes of general practitioners and dermatologists consultation. Patients seek for medical advice for health and cosmetic reasons. Additionally, there is also the wrong belief that melasma could be related to hepatic or renal diseases. Its unspecific and multi-factorial etiology has lead to the use of a diversity of therapeutic alternatives that hinder an optimal sequence and drive to therapeutic failures that are time and money consuming for patients or health institutions. Furthermore, they have negative impact in the patient’s quality of life when their expectations of improvement are not fulfilled.
This situation generates the need to define effective and safe therapeutic guidelines that can provide physicians with accurate elements for decision making, in order to obtain improvement of this condition, as well as to optimize economic resources. One of the strategies to provide physicians with tools that allow following a sequence of therapeutic alternatives is the development of guidelines and algorithms used nowadays in world-wide medical practice.
The value of the present guidelines developed by the Mexican Group for the Study of Pigmentary Disorders (Grupo Mexicano para el Estudio de los Trastornos Pigmentarios) is that they were elaborated based on the clinical experience in Mexican-mestizo patients and therefore applicable in similar populations. This effort constitutes a first step on the pursuit of a standard and integral treatment of melasma and, consequently, an improvement of medical care.


REFERENCES

  1. Taylor SC. Epidemiology of skin diseases in ethnic populations. Dermatol Clin 2003; 21(4): 601-607

  2. Balkrishnan R, Mcmichael AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren M-M. Development and validation of a health-related quality of life instrument for women with melasma. British Journal of Dermatology 2003; 149(3): 572-577

  3. Arellano I, León G, Luna C y cols. Quality of Life in Mexican Patients with Melasma. Cosmetic Dermatology 2006; 19(5): 343-345

  4. Hurley ME, Guevara IL, Gonzáles RM, y Pandya AG. Efficacy of glycolic acid peels in the treatment of melasma. Arch Dermatol 2002; 138(12): 1578-1582

  5. Kang WH, Yoon KH, Lee E-S, Kim J, Yim H, Sohn S, Im S. Melasma: Histopathology characteristics in 56 Korean patients. British Journal of Dermatol 2002; 146(2): 228-237

  6. Ortonne JP, Passeron T. Melanin Pigmentary Disorders: Treatment Update. Dermatol Clin 2005; 23(2): 209-226

  7. Sánchez NP, Pathak MA, Sato S, Fitzpatrick TB, Sánchez JL, Mihm MC Jr. Melasma: A clinical, light microscopic, ultraestructural and immunofluorescence study. J Am Acad Dermatol 1981; 4(6): 698-710

  8. Grin CM, Friedman KP, Grant-Kels JM. Dermoscopy: a review. Dermatol Clin. 2002; 20(4): 641-646

  9. Mayor MC, Robles AD. Estudio comparativo del tratamiento del melasma con acetónido de fluocinolona, hidroquinona y tretinoína vs. hidroquinona y tretinoína. Rev Sanid Milit Mex 2005; 59(5): 318-325

  10. Valkova S. Treatment of Melasma with Glycolic versus Trichloroacetic Acid Peel: Comparison of Clinical Efficacy. Annual Proceedings IMAB 2004; 10(1): 40-41

  11. Rendón M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54(5): 272-281

  12. Vázquez MO, Ocampo-Candini J, Welsh O, Gómez-Flores M y cols. Ocronosis exógena. Presentación de un caso. Actas de Dermatología y de Dermapatologia. Vol 4. núm. 3 y 4, julio-diciembre 2004: 68-70

  13. Torok HM, Jones T, Rich P, Smith S, Tschen E. Hydroquinone 4%, Tretinoin 0.05%, Fluocinolone Acetonide 0.01%: A Safe and Efficacious 12-Month Treatment for Melasma. Cutis 2005; 75(1): 57-62

  14. Rochar C, Fitzpatrick R. The treatment of melasma with fractional photothermolysis: a pilot study. Dermatol Surg. 2005 Dec; 31(12): 1645-1650




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Dermatología Cosmética, Médica y Quirúrgica. 2007;5